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osting by EAbstract TLC–SPE methodologies were developed to ascertain biological interactions of noreth-
indrone acetate and dydrogesterone contraceptives with plasma progesterone receptor proteins.
TLC solvent system for plain and Cu(II) impregnated silica gel plates was n-hexane-n-butanol
(90:10, v/v), which took 20 min to run up to 10.0 cm. The best separation was on Cu(II) impreg-
nated plates due to maximum difference in Rf values and compact spots. The optimized SPE
conditions were pH 2.0 and 3.0 of phosphate buffer (50 mM) for norethindrone acetate and dydro-
gesterone, respectively. The ﬂow rate of plasma and eluting solvent (methanol) through C18 car-
tridge was 0.10 mL/min. The interactions of these contraceptives with progesterone receptor
proteins were analysed by TLC–SPE results, which were supported by modelling using PyMOL
and Autodoc4 softwares. The dydrogesterone was found to be bound strongly than norethindrone
acetate. Attempts have been made to discuss the drugs’ interactions at chemo-supramolecular level.
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lsevier1. Introduction
Nowadays, Asian and African countries are under great pres-
sure due to geometrical growth of population, effecting the
economy and ecosystem of the whole world. The control of this
alarming problem is essential and an urgent need of today. The
population control is being achieved through various
contraceptive approaches. During the last four decades, many
contraceptive methods have been developed and used; and
among them oral dosages are adopted globally (Mansour
2005; Coelingh Bennink et al., 2003). Most commonly used
oral contraceptive drugs are based on estrogens and pro-
gesterone hormones. Among many, norethindrone acetate
Figure 1 Chemical structures of norethindrone acetate and dydrogesterone contraceptives.
236 I. Ali et al.and dydrogesterone Figure 1 are the most commonly used pro-
gestogenic components in hormone replacement therapy
(HRT); with about 80% in the market (Coelingh Bennink
et al., 2003; Li et al., 2005). These progestogens have been used
world widely as oral contraceptive preparations for many years
with sales of about billions of US $ per year (Willard et al.,
2003). In spite of their crucial role in birth control, these med-
ications result into some side and toxic effects, that require the
exploration of the action of mechanism for further improve-
ment in their molecular structures. The interactions of these
drugs with protein are the main core of the mechanism of ac-
tion. Literature indicates that these drugs bind with progester-
one receptor proteins (Madauss et al., 2004) but the binding
proﬁle and pattern is not well known. These types of studies re-
quire the efﬁcient analytical methods and modelling software.
A thorough search of literature indicates only few analytical
methods for monitoring these drugs. Among them, chromato-
graphy is an ideal technique and HPLC (Matlin et al.,1983;
Gonzalo-Lumbreras and Izquierdo-Hornillos, 2000; Sundare-
san et al., 2006) and TLC (Simard and Lodge, 1970) have been
used for this purpose. Of course, HPLC is a more advanced and
popular modality, however, thin layer chromatography (TLC)
has its unique feature of inexpensiveness, parallel chromato-
graphic proﬁles of unknowns and standards and ease of opera-
tion (Stahl1969; Fried and Sharma, 1991; Fried and Sharma,
1996). Therefore, TLC method development is the real demand
for these drugs due to explosion of population in developing
countries, where TLC suits well as an ideal technique (inexpen-
sive).The monitoring of analytes in plasma needs sample prep-
aration before loading onto TLC. It has been observed that
about 80 percent chromatographers are using solid phase
extraction (SPE) as the versatile method of sample preparation
for plasma (Ali et al., 2008). It is interesting to observe that no
method is available for monitoring these drugs in plasma by
using SPE–TLC combination, that we found ideal for third
world countries. In view of these facts, attempts have been
made to develop inexpensive, fast, selective and reproducible
SPE–TLC methods for analyses of the reported contraceptives
in human plasma. Based on the results obtained and modelling,
efforts were made to explain the interactions of these drugs with
progesterone receptor protein for further research. The results
of these ﬁndings are discussed herein.
2. Experimental
2.1. Chemicals, reagents and instruments
Fresh frozen human plasma (Mfg. Licence No. 504) was pur-
chased from Rotary Blood bank, New Delhi India. Methanol,n-hexane, n-butanol and silica gel G, disodium hydrogen phos-
phate and o-phosphoric acids were purchased from Merck,
India. Ferric chloride, sulphuric acid and glacial acetic acids
were obtained from Qualigens, India. Standard solutions
(0.10 mg mL1) of these drugs were prepared in methanol.
Norethindrone acetate and dydrogesterone were detected on
TLC plates by developing a new reagent. The reagent was pre-
pared by dissolving 500 mg ferric chloride in a mixture of sul-
phuric acid (20 mL) and glacial acetic acid (10 mL) followed
by water dilution up to 50 mL. Puriﬁed water was prepared
using a Millipore Milli-Q (Bedford, MA USA) water
puriﬁcation system., Sep-Pak C18 1 mL barrel size cartridges
containing 50 mg of sorbent (particle size 55–105 lm and pore
size 125 A˚) were purchased from Waters USA (Cat.No.
WAT054955). pH meter of Control Dynamics (model APX
175 E/C), spectrophotometer of Perkin Elmer (model EZ201),
solid phase extraction unit of VARIAN and centrifuge (model
C854/49/06) of Remi were used. PyMOL visualization tool and
Autodoc4 software were used for modelling purposes of drugs
binding with progesterone receptor.
2.2. Extraction of drugs from commercial tablets
Norethindrone acetate and dydrogesterone were extracted
from commercially available tablets. Norethindrone acetate
was extracted from ﬁve regestrone tablets (batch No.
R67B05D) of Novartis India Limited, Mahad, (Maharashtra),
India. Similarly, dydrogesterone was extracted from ﬁve
Duphastone formulation (batch No. L7301) of Solvay Pharma
India Limited, Mumbai, India. Five tablets of each drug were
weighed and crushed to powder separately, respectively. The
powdered tablets were extracted with methanol (100 mL), sep-
arately, by heating at 80 C. The drug mixture was centrifuged
and supernatant was separated. The residue was extracted two
more times with the same amount of methanol separately. All
methanol fractions were combined together to get 300 mL.
This methanol was evaporated under vacuum on water bath
to 15 mL, which was allowed to crystallize in freeze at 10 C.
The mother liquor was decanted and the crystals were washed
with a little amount of n-hexane. The purity of the drugs was
ascertained by melting point, UV and IR spectra.
2.3. Preparation of TLC plates
TLC plates (10 cm · 15 cm · 0.5 mm) were prepared in the
laboratory by spreading slurry of silica gel G (50 g) in
100 mL Millipore water. These plates were dried overnight in
an oven at 80 C. For impregnated TLC plates, silica gel slurry
was prepared with Millipore water containing 0.10 g each of
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and ZnSO4Æ7H2O in 100 mL Millipore water individually and,
respectively. The plates were activated by heating in an oven.
2.4. Solid-phase extraction (SPE)
The blank experiments were carried out by mixing 1.0 mL of
each drug (1.0 mg mL1) into 5.0 mL Millipore water individ-
ually and separately. The spiked sample was vortexed for
2 min, kept for 30 min, mixed with 15.0 mL acetone and centri-
fuged at 1000 rpm for 5 min to separate the supernatant. The
supernatant was evaporated to dryness and the residue was
re-dissolved in 10.0 mL phosphate buffer (50 mM, pH 2.0)
for norethindrone acetate and pH 3.0 for dydrogesterone. A
Sep-Pak Vac C18 cartridge (1.0 ml Waters, USA) was pre-con-
ditioned with 2.0 mL methanol followed by 5.0 mL Millipore
water. Spiked samples were passed through the cartridge with
0.1 mL ﬂow rate followed by cartridge washing with 2.0 mL
Millipore water at the same ﬂow rate. The cartridge was dried
by passing hot air and the drugs were eluted by 10.0 mL meth-
anol at 0.1 mL per minute ﬂow rate. The eluted methanol was
concentrated under vacuum to 0.5 mL. This solution was used
for TLC studies. The same procedure was adopted to analyse
these drugs in human plasma.
2.5. Thin layer chromatography
TLC conditions were developed for these drugs on plain and
impregnated plates. TLC plates were spotted by these drugs
at 10.0 ng level with the help of graduated capillaries
(10.0 lL) and the chromatograms were developed in TLC
chamber pre-equilibrated with solvents for 30 min. The chro-
matograms were developed up to 10.0 cm for 20 min by using
n-hexane-n-butanol (90:10, v/v) at 20 ± 2 C. The exhaustive
experiments were carried out to optimize the chromatographic
conditions. The reported solvent system was optimized by
increasing the concentrations of n-butanol. After development
the plates were dried at 80 C and the spots were detected by
spraying the above cited reagent followed by heating of plates
at 80 C for 1 h. Solvent system was optimized by varying the
concentrations of n-hexane and n-butanol. The analyses of
these drugs; after extraction by SPE; were also carried out
by TLC using the same developed method. The qualitative
determination of these drugs in plasma was ascertained by
comparing the Rf values of these with those of standards.
For quantitative analyses the spots (10 lL) from ﬁve TLC
plates were scratched and dissolved in methanol (3.0 mL),
which was concentrated to 1.0 mL for determining theirTable 1 Rf values and detection limits of norethindrone acetate and
different metal ions.
Contraceptive drugs Rf values on plain
silica gel layers
Rf values on impreg
Fe(II) Co(I
Norethindrone acetate 0.82 0.91D 0.92
Dydrogesterone 0.73 0.68 0.74D
Experimental conditions: D: diffused spots, solvent system: n-Hexane:n-
room temperature: 20 ± 2 C, detecting reagent: 500 mg FeCl3 in a mixtu
by water.concentrations by UV–Vis. Spectrophotometer at 300 nm
and 298 nm wavelengths for norethindrone acetate and dydro-
gesterone, respectively. The calibration curves were linear for
both drugs from 0.1 to 0.01 mg/mL concentrations. For vali-
dation, all the experiments were carried out ﬁve times under
the identical experimental conditions and data were validated.
3. Result and discussion
3.1. Chromatography
Rf values of norethindrone acetate and dydrogesterone were
obtained by dividing the distance travelled by these drugs by
the solvent front (10.0 cm). The results are given in Table 1,
which indicate greater Rf value of norethindrone acetate than
dydrogesterone with 0.40 and 0.10 ng as limits of detection
(LOD) of these pharmaceuticals, respectively. To optimize
the chromatographic condition, various combinations of n-
hexane and n-butanol were tried but the best separation was
achieved by using n-hexane:n-butanol (90:10, v/v) solvent sys-
tem on plain TLC plates. The variation of mobile phase com-
position was carried out on plain TLC plates by increasing
amount of n-butanol. The effect of mobile phase compositions
on Rf values is given in Figure 2, which indicates that Rf values
increased sharply with 1.0–10.0% of n-butanol but became al-
most constant after this composition. This may be due to rapid
increase in polarity from 1.0% to 10.0% n-butanol while the
further increase of n-butanol does not increase polarity; as
the concentration of low polarity n-hexane becomes negligible.
Furthermore, this ﬁgure depicts that Rf values of norethin-
drone acetate are slightly higher than dydrogesterone at all
compositions of the mobile phase, which are the characteristic
features of these drugs. Furthermore, attempts have been made
to improve more separation and, therefore, some TLC experi-
ments on metal ions impregnated plates were also carried out.
The selected metal ions for impregnation were Fe(II), Co(II),
Ni(II), Cu(II) and Zn(II) of 0.1% concentration each sepa-
rately. The results on impregnated plates were also recorded
in Table 1. A comparison of the separation on plain and
impregnated TLC plates from Table 1 clearly shows better re-
sults on copper impregnated TLC plates with maximum differ-
ence of Rf values and compact spot. On the other hand, the
diffused spots were observed on all other metal ions impreg-
nated TLC plates. TLC chromatograms of these two drugs
on plain and copper impregnated plates are shown in Figure
3 which indicate better separation of these drugs on copper
metal ion impregnated plates. It is very interesting to observe
that the color of both the spots was brown on copper impreg-dydrogesterone on plain and impregnated silica gel layers with
nated silica gel layers LOD (ng)
I) Ni(II) Cu(II) Zn(II)
0.92D 0.92 0.94 0.40
0.84 0.82 0.87D 0.10
butanol (90/10,v/v), solvent front: 10.0 cm, developing time: 25 min,
re of H2SO4 (20 mL) and glacial acetic acid (10 mL); diluted to 50 mL
Figure 2 The effect of mobile phase composition on Rf values of
norethindrone acetate and dydrogesterone on plain silica gel
plates.
238 I. Ali et al.nated plates while it was yellow on plain plates. This behaviour
is due to the complex formation of these drugs with copper
metal ion.
3.2. Solid phase extraction (SPE)
The recovered concentrations of norethindrone acetate and
dydrogesterone were 0.079 and 0.073 mg from human plasmaFigure 3 Chromatograms of northindrone acetate and dydrogesteron
layer. N: Norethindrone acetate, D: Dydrogesterone and M: Mixtureafter 30 min. The percentage recoveries of these drugs were cal-
culated and found to be 79% and 73%, respectively. These
concentrations were calculated by applying the correction
factors due to the blank experiments. The decrease in the con-
centrations of these drugs (21% of norethindrone acetate and
27% of dydrogesterone) may be due to their binding with
plasma proteins. The optimization of SPE includes pH of
phosphate buffer, ﬂow rate of plasma sample and eluting sol-
vents, and use of the different eluting solvents. SPE experiment
was carried out with pH range of 1.0–8.0 and the maximum
recoveries of these drugs were obtained at pH 2.0 for noreth-
indrone acetate and at pH 3.0 for dydrogesterone. The differ-
ent ﬂow rates of plasma samples (0.10–0.50 mL/min.) were
examined to optimize the SPE conditions and poor recoveries
were obtained at high ﬂow rate while it was maximum at low
ﬂow rate. The same situations were obtained with eluting sol-
vents. The optimized ﬂow rates for both plasma samples and
eluting solvents were 0.10 mL/min. Attempts have been made
to optimize SPE conditions by using different solvents, such
as methanol, ethanol, ethyl acetate and dichloromethane. Be-
sides, the optimization was also carried out by eluting the re-
ported drugs with these solvents with and without different
amounts of acetic acid or triﬂuoroacetic acid. As a result of
an extensive experimentation the best eluting solvent was pure
methanol for these drugs. It is due to the fact that the polarity
of methanol is quite enough to elute these drugs from C18
cartridge under the reported experimental conditions.
3.3. Interaction of drugs with plasma proteins
The reported percentage recoveries clearly indicate that
dydrogesterone binds more with proteins in comparison toe on (A) plain silica gel layer and (B) Cu(II) impregnated silica gel
of both drugs. Experimental conditions as given in Table 1.
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more binding sites in former than in latter drug. Attempts have
been made to verify and conﬁrm the experimental binding
results with the help of modelling by using PyMOL visualiza-
tion tool and Autodoc4 softwares. Both drugs bind to the pro-
gesterone receptor forming the progesterone receptor binding
complexes (Madauss et al., 2004). Norethindrone acetate and
dydrogesterone are structurally similar except that norethin-
drone acetate and dydrogesterone have 22 and 23 non-hydro-
gen atoms (one extra C19 methyl group and one extra double
bond present at C6–C7 position of dydrogesterone; as shown
inFigure 1). The carbonyl ketonic groups of both progestogens
bind to the amino acid residues i.e. Gln725, Arg766 and
Phe788 of progesterone receptor and water molecule (W)
through hydrogen bonding and Van der Waals forces forming
four bonds; as shown in Figure 4A and B. C19 methyl group in
dydrogesterone projects into a bubble like pocket in progester-
one receptor providing Van der Waals forces while such a
methyl group is not present in norethindrone acetate; lacking
Van der Waals forces. Besides, C20 methyl keto group of
dydrogesterone also enhances Van der Waals interactionsFigure 4 Visualisation and chemical models of interactions of (A)
receptor, respectively.and hydrogen bonding with two nearest amino acid residues
i.e. Asp 719 and Thr 894 of the progesterone receptor (Wil-
liams and Sigler, 1998). This situation causes more binding
of dydrogesterone than norethindrone acetate (Madauss
et al., 2004) to the protein and consequently the progesterone
receptor. Besides, high afﬁnity of dydrogesterone may be
attributed to the presence of one extra double bond at C6–C7
position, which provides the rigid conformation to the mole-
cule suitable for the interaction with the progesterone recep-
tors (Colombo et al., 2006).
Norethindrone acetate has a larger group at C17-a- (an
ethynyl) and a smaller substituent at C17-b- (a hydroxyl
group). The C17-b- group forms hydrogen bond with side
chain of a residue of Asn719 (Madauss et al., 2004). Of course,
a novel water mediated interaction between C17-b-hydroxyl
group of norethindrone acetate and Asn719 enhanced proges-
terone receptor binding afﬁnity but our modelling suggests
that norethindrone binds in the same orientation as dydroges-
terone resulting into squeezing out of water molecule for opti-
mal position and the hydrogen bond becomes weaker (Figure
4). In addition, dydrogesterone has one extra double bond,norethindrone acetate and (B) dydrogesterone with progesterone
240 I. Ali et al.which provides interactions with phenyl ring of aromatic ami-
no acids of progesterone receptor protein. The modelling visu-
alization, analyses, comparison of all experimental results, all
bindings and forces patterns indicate greater binding of dydro-
gesterone than norethindrone acetate.
4. Validation of the methods
The validation of the developed method was determined by
carrying out ﬁve sets (n= 5) of the chromatographic and solid
phase extraction procedures under the identical experimental
conditions. The regression analysis was carried out using
Microsoft Excel program. The standard deviation (SD) and
correlation coefﬁcients (R) for TLC were in the range of
±0.040–0.041 and 0.9997–0.9996, respectively, while the con-
ﬁdence levels varied from 99.4 to 99.5 for both contraceptives.
Similarly, the values of standard deviation and correlation
coefﬁcients for SPE were from ±0.070 to ±0.071 and
0.9998 to 0.9996, respectively, for both drugs while the values
of conﬁdence level were 99.4 and 99.5 for norethindrone ace-
tate and dydrogesterone, respectively. The correlation coefﬁ-
cients for calibration curves were higher than 0.997 as
determined by least square analysis. The detection limits for
norethindrone acetate and dydrogesterone were 0.40 and
0.10 ng, respectively.
5. Conclusion
The present article describes the determination of dydrogester-
one and norethindrone acetate in plasma by using TLC–SPE
methodologies. The results indicate that the developed method
is inexpensive, reproducible, selective and efﬁcient, which can
be used to analyse these contraceptives in any blood samples.
The detection limits are quite low, which is the requirement of
today. The bonding patterns and mechanisms of these drugs
have been developed and they clearly indicate higher binding
of dydrogesterone than norethindrone acetate. This statement
is being supportive by the fact that dydrogesterone is a more
effective contraceptive than norethindrone acetate. The re-
ported results are useful for further development of more effec-
tive oral contraceptives.Acknowledgement
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